يعرض 141 - 160 نتائج من 286 نتيجة بحث عن '(( significant effect decrease ) OR ( significantly ((lower decrease) OR (mean decrease)) ))~', وقت الاستعلام: 0.53s تنقيح النتائج
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145

    Key safety measures including adverse events. حسب Anuja Dokras (8679261)

    منشور في 2025
    "…Waist circumference (mean change (MC) −2.23 cm; 95% CI [−3.98, −0.49]; <i>p</i> = 0.01), BMI (MC −0.49 kg/m<sup>2</sup>; 95% CI [−0.88, −0.10[; <i>p</i> = 0.01), and android fat mass measured by DXA (MC −167 g; 95% CI [−264, −71[; <i>p</i> < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. …"
  6. 146
  7. 147
  8. 148
  9. 149

    Risk of bias across 22 included studie. حسب Kuo-Chuan Hung (8587392)

    منشور في 2024
    "…Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], −0.94; 95%CI, −1.26 to −0.62) and 4–6-week (SMD, −0.89; 95%CI, −1.25 to −0.53) follow-ups. …"
  10. 150

    An overview of the selection process for studies. حسب Kuo-Chuan Hung (8587392)

    منشور في 2024
    "…Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], −0.94; 95%CI, −1.26 to −0.62) and 4–6-week (SMD, −0.89; 95%CI, −1.25 to −0.53) follow-ups. …"
  11. 151

    Characteristics of studies (<i>n</i> = 22). حسب Kuo-Chuan Hung (8587392)

    منشور في 2024
    "…Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], −0.94; 95%CI, −1.26 to −0.62) and 4–6-week (SMD, −0.89; 95%CI, −1.25 to −0.53) follow-ups. …"
  12. 152
  13. 153
  14. 154

    Multiple comparisons after ANOVA(CR10). حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"
  15. 155

    Homogeneity test of CR10. حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"
  16. 156

    Illustration of the fNIRS device worn. حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"
  17. 157

    Analysis of variance of HbO<sub>2</sub> in bilateral PFC. حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"
  18. 158

    fNIRS equipment coordinates. حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"
  19. 159

    Changes of muscle oxygen saturation. حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"
  20. 160

    Analysis of variance of CR10. حسب Xinyu Dai (5100731)

    منشور في 2025
    "…A series of multiple comparisons demonstrated that the CR10 in the IMW group exhibited a significantly lower value than that observed in the placebo and control groups (<i>p</i> < 0.001). …"